Regen BioPharma (RGBPP) Common Equity (2016 - 2025)
Historic Common Equity for Regen BioPharma (RGBPP) over the last 12 years, with Q4 2025 value amounting to -$6.6 million.
- Regen BioPharma's Common Equity fell 1574.13% to -$6.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.6 million, marking a year-over-year decrease of 1574.13%. This contributed to the annual value of -$6.3 million for FY2025, which is 2038.98% down from last year.
- According to the latest figures from Q4 2025, Regen BioPharma's Common Equity is -$6.6 million, which was down 1574.13% from -$6.3 million recorded in Q3 2025.
- Regen BioPharma's Common Equity's 5-year high stood at -$4.9 million during Q4 2022, with a 5-year trough of -$76.7 million in Q1 2022.
- Over the past 5 years, Regen BioPharma's median Common Equity value was -$5.7 million (recorded in 2024), while the average stood at -$10.2 million.
- Per our database at Business Quant, Regen BioPharma's Common Equity plummeted by 141358.23% in 2022 and then skyrocketed by 9357.68% in 2023.
- Regen BioPharma's Common Equity (Quarter) stood at -$9.8 million in 2021, then soared by 49.93% to -$4.9 million in 2022, then decreased by 7.3% to -$5.2 million in 2023, then fell by 8.35% to -$5.7 million in 2024, then dropped by 15.74% to -$6.6 million in 2025.
- Its Common Equity stands at -$6.6 million for Q4 2025, versus -$6.3 million for Q3 2025 and -$5.8 million for Q2 2025.